AKBA at a glance
Akebia Therapeutics, Inc. (AKBA, SEC CIK 1517022) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Akebia Therapeutics, Inc. (AKBA) shares worth $62.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ostrowski Erik on June 29, 2026 of 56,019 shares at $1.11 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $236.2M
- +47.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $62.9M · −3 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 1.02 · Item 1.01 · Item 2.03 · Item 3.02 · Item 7.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $36.9M, down 37% YoY from $58.8M
- Net loss $14.4M vs $0.5M net income YoY, operating margin -31.1% vs 7.6%
- Worst performer Auryxia revenue $20.0M, down 53% YoY from $42.5M
- Cash $160.2M including restricted cash at September 30, down from $186.5M year-end 2025
- Nine-month operating cash flow $(15.4)M vs $36.9M, outlook pressured by generics and lower Vafseo pricing in 2027
Risk Factors
- Newly triggered regulatory risk: 2027 ESRD Rule creates quarterly Vafseo reimbursement adjustments after TDAPA expiration on January 1, 2027
- Most material commercial update: Teva’s March 2026 generic Auryxia approval caused significant sales-volume reduction
- Regulatory safety risk: Vafseo carries a boxed warning for increased death, myocardial infarction, stroke, and thromboembolic risks
- Near-term market risk: Vafseo revenue was lower than anticipated in Q3 2026 as customers reduced inventory ahead of TDAPA expiration
- Financial liquidity risk: $159.3 million cash depends on refinancing debt before principal payments begin January 1, 2027
AI summary of the AKBA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.02: Termination of a Material Definitive Agreement
- Kreos Term Loan Facility terminated alongside the new loan agreement on January 29, 2024
- Akebia’s obligations under the prior facility paid in full and discharged
Item 1.01: Entry into a Material Definitive Agreement
- $60.0M initial senior secured term loan funded, with up to $80.0M additional discretionary borrowing
- Net proceeds approximately $58.6M, used partly to repay Kreos’ $55.0M prior term loan
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
- Investor impact depends on the referenced agreement’s payment terms, amount, maturity and financing purpose
Item 3.02: Unregistered Sales of Equity Securities
- Warrant terms described under Item 1.01 govern the unregistered equity issuance
- Potential shareholder dilution depends on warrant count, exercise price, and expiration terms disclosed under Item 1.01
Item 7.01: Regulation FD Disclosure
- Press release announces execution of a Loan Agreement
- Financing terms and obligations require review of Exhibit 99.1
Item 8.01: Other Events
- Debt repayment removes the Prior Loan Agreement from the company’s financing obligations
- Management expects existing cash and operating revenues to fund the current plan for at least two years
Item EX-99.1: Item EX-99.1
- $60 million senior secured tranche fully funded on November 12, 2026
- Proceeds repaid BlackRock’s $55 million loan facility in full
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced
- Recent business highlights included alongside financial results
Item EX-99.1: Item EX-99.1
- Q3 revenue $36.9M, down from $58.8M, driven by Auryxia revenue falling to $20.0M amid generic competition
- Vafseo revenue $14.8M, while active patients reached approximately 11,500, up 140% year over year
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days
- No immediate delisting: initial 180-day cure period runs through April 19, 2027
AI summaries of AKBA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AKBA
Don't miss the next AKBA filing
- Alerts as it files. A push when AKBA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AKBA, by share count.
- Ask anything. An AI agent that reads every AKBA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Butler John P. | M | Aug 6, 2026 | 350,000 | - |
| Butler John P. | M | Aug 6, 2026 | 350,000 | $0.63 |
| Ostrowski Erik | Sell | Jun 29, 2026 | 56,019 | $1.11 |
| ZUMWALT LEANNE M | A | Jun 17, 2026 | 53,600 | - |
| ADAMS ADRIAN | A | Jun 17, 2026 | 53,600 | - |
| ZUMWALT LEANNE M | A | Jun 17, 2026 | 35,700 | - |
| ROGERS MICHAEL W | A | Jun 17, 2026 | 35,700 | - |
| Wolf Myles | A | Jun 17, 2026 | 53,600 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $160.2M | $236.2M |
| Operating Income | - | -$50.5M | $23.5M |
| Net Income | -$51.9M | -$69.4M | -$5.3M |
| Op. Margin | - | -31.5% | 9.9% |
| Net Margin | - | -43.3% | -2.3% |
| Balance Sheet | |||
| Total Assets | - | $220.7M | $376.6M |
| Equity | -$30.6M | -$49.2M | $32.6M |
| ROE | 169.8% | 141.1% | -16.4% |
| Per Share | |||
| EPS | $-0.28 | $-0.33 | $-0.02 |
| Cash Flow | |||
| Operating CF | - | -$40.7M | $68.0M |
| CapEx | $0 | $33K | $291K |
Source: XBRL data in Akebia Therapeutics, Inc. (AKBA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AKBA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $62.9M |
| Q2 2026 | 30 | $81.2M |
| Q1 2026 | 29 | $95.6M |
| Q4 2025 | 25 | $125.9M |
| Q3 2025 | 26 | $220.3M |
| Q2 2025 | 27 | $259.3M |
| Q1 2025 | 25 | $81.3M |
| Q4 2024 | 21 | $50.6M |
- Two Sigma Investments+3.63M (+149%)
- BlackRock+1.10M (+5%)
- Vanguard Portfolio Management LLC+1.00M (+40%)
- Goldman Sachs Group+734.5K (+20%)
- Renaissance Technologies LLC+659.9K (+54%)
- AQR Capital Management−2.86M (-31%)
- Millennium Management−1.41M (-44%)
- Citigroup−1.11M (-99%)
- Citadel Advisors LLC−676.5K (-39%)
- Morgan Stanley−394.7K (-56%)
- StoneX Group Inc.+17.1K
- FMR LLC (Fidelity)−1.87M
- Mangrove Partners−667.0K
- Dimensional Fund Advisors−358.6K
- Raymond James Financial−57.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AKBA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 4 | Mar 5, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AKBA SEC filings: frequently asked questions
Which institutions hold AKBA stock?
As of September 30, 2026, the largest Akebia Therapeutics, Inc. (AKBA) holders among the 13F filers tracked by SignalX were BlackRock ($19.4 million), Vanguard Capital Management LLC ($10.4 million), AQR Capital Management ($5.8 million), Two Sigma Investments ($5.6 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AKBA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.2 million (up 47.5% from FY2024) and a net loss of $5.3 million. Diluted EPS was -$0.02. The figures come from the XBRL data in the 10-K.
What did AKBA report in its latest 8-K?
Akebia Therapeutics, Inc. (AKBA) filed an 8-K on November 16, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Kreos Term Loan Facility terminated alongside the new loan agreement on January 29, 2024.
What are the latest AKBA SEC filings?
Akebia Therapeutics, Inc. (AKBA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 10, 2026.
What is AKBA's SEC CIK number?
Akebia Therapeutics, Inc. (AKBA)'s SEC Central Index Key (CIK) is 1517022. EDGAR lists every AKBA filing under that number.
Ask anything about AKBA
The research agent reads AKBA's filings, financials, insider trades and 13F holders, then answers with sources.